Preclinical graft study supports Cytori’s proposed mechanism of action

NewsGuard 100/100 Score

Cytori Therapeutics (NASDAQ: CYTX) reported results from a preclinical cell-enriched fat grafting study supporting the safety and efficacy of Cytori’s method for enriching fat grafts with adipose-derived regenerative cells (ADRCs).

The study tracked the expression of important growth factors within the cell-enriched fat grafts and examined the time course of the effect of ADRCs in a transplanted graft and the temporal role of growth factor expression. The results were presented today at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium (Poster #4124).

The study results demonstrate that the ADRCs used to enrich the fat grafts were active for several days after implantation and secreted several growth factors within the fat grafts. Gene expression for the specific growth factors associated with the restoration and repair of blood vessels was initially very high but subsided to undetectable levels after three weeks.

The results suggest that the efficacy of the ADRCs may be due in part to their ability to secrete multiple important growth factors locally within the graft. In addition, the subsequent down regulation of these growth factors has positive long-term safety implications since continued, high level expression of these growth factors may not be desirable. Overall, the initial local secretion of growth factors by ADRCs, followed by the rapid reduction in growth factor levels supports Cytori’s proposed mechanism of action, i.e. the transplanted cells swiftly impart regenerative benefit and then become quiescent.

According to the study design, mice were injected with a graft of mouse fat mixed with human ADRCs that were isolated using Cytori’s Celution® 800/CRS System. Samples of the ADRC enriched grafts were harvested at seven different time points over a period of 84 days. The samples were tested for the presence of human DNA and RNA, which can be used to detect key human specific growth factors, IGF-1 and VEGF-A.

Over the course of the study, the presence of human DNA was shown to decrease rapidly, with only 1% to be detected by day 14. No human DNA could be detected after day 56. Levels of IGF-1 and VEGF-A, as indicated by the presence of human RNA, also decreased, with neither detected after day 28.

Source: Cytori.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Boosting curcumin's absorption and effectiveness for disease prevention and therapy